[go: up one dir, main page]

MX2018003311A - Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario. - Google Patents

Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario.

Info

Publication number
MX2018003311A
MX2018003311A MX2018003311A MX2018003311A MX2018003311A MX 2018003311 A MX2018003311 A MX 2018003311A MX 2018003311 A MX2018003311 A MX 2018003311A MX 2018003311 A MX2018003311 A MX 2018003311A MX 2018003311 A MX2018003311 A MX 2018003311A
Authority
MX
Mexico
Prior art keywords
nucleic acid
intermediate compound
producing same
guna
crosslinked nucleic
Prior art date
Application number
MX2018003311A
Other languages
English (en)
Inventor
Obika Satoshi
Kawanishi Eiji
Sawamoto Hiroaki
Yamakoshi Shuhei
Arai Yuuki
Kumagai Shinji
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2018003311A publication Critical patent/MX2018003311A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona un método para producir ácido nucleico artificial entrelazado con guanidina (abreviado en lo sucesivo como GuNA), y un compuesto intermedio para la producción del mismo; específicamente, la presente invención proporciona un método para producir un compuesto representado por la fórmula general I: (en la fórmula, R1, R2, R3, R4, R5, R6, m y el anillo A son como se define en la especificación) o una sal del mismo en donde se hace reaccionar un agente de reducción con un compuesto representado por la fórmula general II: (en la fórmula R1, R2, R3, R4, R5, R6, m y el anillo A' son como se definen en la especificación).(ver formulas).
MX2018003311A 2015-09-18 2016-09-20 Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario. MX2018003311A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015185730 2015-09-18
JP2016039351 2016-03-01
PCT/JP2016/077748 WO2017047816A1 (ja) 2015-09-18 2016-09-20 架橋型核酸ＧｕＮＡ、その製造方法および中間体化合物

Publications (1)

Publication Number Publication Date
MX2018003311A true MX2018003311A (es) 2019-02-07

Family

ID=58289462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003311A MX2018003311A (es) 2015-09-18 2016-09-20 Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario.

Country Status (14)

Country Link
US (1) US10961269B2 (es)
EP (2) EP3974436A1 (es)
JP (4) JP6994197B2 (es)
KR (1) KR20180057651A (es)
CN (1) CN108137638B (es)
AU (1) AU2016324126A1 (es)
BR (1) BR112018005284A2 (es)
HK (1) HK1251577A1 (es)
MX (1) MX2018003311A (es)
PH (1) PH12018500582A1 (es)
RU (1) RU2018113811A (es)
SG (1) SG11201802190UA (es)
TW (1) TW201718618A (es)
WO (1) WO2017047816A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
KR102131898B1 (ko) * 2017-10-31 2020-07-08 주식회사 노벨티노빌리티 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
JP2019119739A (ja) * 2017-12-28 2019-07-22 国立大学法人岐阜大学 ヌクレオシド誘導体の製造方法
WO2020100826A1 (ja) 2018-11-12 2020-05-22 田辺三菱製薬株式会社 架橋型人工核酸ａｌｎａ
JP7667074B2 (ja) 2019-03-29 2025-04-22 田辺三菱製薬株式会社 Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物
EP4151237A4 (en) * 2020-05-12 2024-08-14 Mitsubishi Tanabe Pharma Corporation Compound, method and pharmaceutical composition for regulating expression of ataxin 3
JP2023130528A (ja) * 2020-06-24 2023-09-21 田辺三菱製薬株式会社 Ｐｌｐ１発現を調節するための化合物、方法及び医薬組成物
JP2024105742A (ja) * 2021-05-26 2024-08-07 ルクサナバイオテク株式会社 心疾患治療薬
US20230383296A1 (en) * 2022-03-17 2023-11-30 Aligos Therapeutics, Inc. Modified gapmer oligomers and methods of use thereof
JPWO2024101446A1 (es) * 2022-11-10 2024-05-16
EP4640693A1 (en) 2022-12-21 2025-10-29 Mitsubishi Tanabe Pharma Corporation Method for producing production intermediate, production intermediate thereof, and method for producing crosslinked artificial nucleic acid intermediate by using same
EP4678626A1 (en) 2023-03-06 2026-01-14 Spera Pharma, Inc. Long-chain alkenyloxy-substituted benzoyl derivative and oligonucleotide synthesis method using same
WO2025206092A1 (ja) * 2024-03-27 2025-10-02 田辺三菱製薬株式会社 Ｍｙｏｒｅｇｕｌｉｎ発現を調節するための化合物及び医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09328497A (ja) * 1996-04-12 1997-12-22 Yamasa Shoyu Co Ltd ４’−フルオロメチルヌクレオシド
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP2341058A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
JP4383176B2 (ja) 2002-02-13 2009-12-16 武 今西 ヌクレオシド類縁体およびそのヌクレオチド類縁体を含むオリゴヌクレオチド誘導体
WO2003095467A1 (en) * 2002-05-08 2003-11-20 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
EP1661905B9 (en) * 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
PL1835035T3 (pl) * 2006-03-15 2010-07-30 Explora Laboratories Sa Sposób immobilizowania komórek na żywicy
WO2007145593A1 (en) * 2006-06-15 2007-12-21 Jyoti Chattopadhyaya Conformationally constrained 2' -n,4' -c-ethylene-bridged thymidine (aza-ena-t)
WO2008006369A1 (en) * 2006-07-14 2008-01-17 Santaris Pharma A/S Adenosine receptor antagonists
WO2011052436A1 (ja) * 2009-10-29 2011-05-05 国立大学法人大阪大学 架橋型人工ヌクレオシドおよびヌクレオチド
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2842103A1 (en) 2011-07-19 2013-01-24 University Of Idaho Embodiments of a probe and method for targeting nucleic acids
EP2899197B1 (en) * 2012-09-21 2017-03-22 Osaka University Oligonucleotide and artificial nucleoside having guanidine bridge
WO2014066239A1 (en) * 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014109384A1 (ja) * 2013-01-10 2014-07-17 塩野義製薬株式会社 架橋型核酸誘導体の製造方法
WO2014124952A1 (en) * 2013-02-12 2014-08-21 Syddansk Universitet "clickable" alkyne-lna oligonucleotides
US9862743B2 (en) * 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
WO2016145142A1 (en) * 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物

Also Published As

Publication number Publication date
CN108137638A (zh) 2018-06-08
SG11201802190UA (en) 2018-04-27
TW201718618A (zh) 2017-06-01
JP2023075302A (ja) 2023-05-30
EP3351548A4 (en) 2019-06-12
PH12018500582A1 (en) 2018-09-10
CN108137638B (zh) 2022-05-03
US10961269B2 (en) 2021-03-30
WO2017047816A1 (ja) 2017-03-23
JP2024153835A (ja) 2024-10-29
EP3351548A1 (en) 2018-07-25
HK1251577A1 (en) 2019-02-01
AU2016324126A1 (en) 2018-05-10
JPWO2017047816A1 (ja) 2018-07-05
BR112018005284A2 (pt) 2018-12-11
EP3974436A1 (en) 2022-03-30
EP3351548B1 (en) 2025-08-20
JP6994197B2 (ja) 2022-01-14
KR20180057651A (ko) 2018-05-30
US20180251488A1 (en) 2018-09-06
RU2018113811A (ru) 2019-10-18
JP2022033869A (ja) 2022-03-02

Similar Documents

Publication Publication Date Title
MX2018003311A (es) Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario.
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
CL2017003404A1 (es) Compuestos antibacterianos
MX2021016054A (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales.
MX388826B (es) Compuesto peptidico.
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
EA029568B8 (ru) Бигетероарильные соединения и их применения
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
MX2019005254A (es) Proceso para la purificacion de pirazolpiridazinas.
ECSP20080995A (es) Derivados de tetrahidrotienopiridina n–sustituidos y sus usos
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
MX382702B (es) Nuevos compuestos de sulfonilaminobenzamida como antihelminticos.
CR20150594A (es) N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas
MX2020003922A (es) Proceso para producir compuestos de piridazinona herbicida.
UY37211A (es) Proceso para la preparacion de piridinilimidazolonas
UY37210A (es) Proceso para la preparación de piridinilimidazolonas
RU2013113468A (ru) 2-({[(1s,2r,5s)-6,6-диметилбицикло[3.1.1]гепт-2-ил]метил}сульфинил)этановая кислота, обладающая антиагрегационным действием
MX2016005220A (es) Tinturas acidas, proceso para su produccion y su uso.